Skip Navigation Links
Skip Navigation Links

GI - Rectal Cancer

GI - Colon Cancer Trials in St. Louis, MO


MATCH: Molecular analysis for therapy choice. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphoma. EAY131 (NCT02465050)  (MBMC Contact: Henry Robinson 314-996-5865)

Phase II/III Randomized Study of Neoadjuvant FOLFOX Therapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil Versus Chemoradiation Comprising Fluorouracil or Capecitabine and Radiation Therapy in Patients With Locally Advanced Rectal Cancer Undergoing Low-Anterior Resection With Total Mesorectal Excision  (No Drugs Provided) NCTG N1048 (PROSPECT) (NCT01515787) (MBMC Contact: Henry Robinson 314-996-5865)  QOL component closed to new patient accrual.  (ONLY AVAILABLE AT MBMC - MUST BE RT CREDENTIALED, CRA's must be PRO-CTCAE CREDENTIALED, SURGEON MUST BE CREDENTIALED)

Phase II clinical trial platform of sensitization utilizing total neoadjuvant therapy (TNT) in rectal cancer NRG GI002 (NCT02921256)  (MBMC Contact:  Henry Robinson 314-996-5865)  ONLY AVAILABLE CURRENTLY AT MBMC - MUST BE RT CREDENTIALED (see protocol for details on how to obtain credentialing)

 Implementation of a prospective financial impact assessment tool in patients with metastatic colorectal cancer S1417CD (NCT02728804)  (MBMC Contact:  Henry Robinson 314-996-5865)



All contents 2007 Heartland Cancer Research St. Louis, MO. All rights reserved. Privacy Policy